Sign In
Buy NKTR
$59.23
+0.670 (+1.14%)
At Close: Jun 03, 2026
NEW YORK, March 27, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Nektar Therapeutics (NASDAQ: NKTR).
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their Options If you purchased or acquired
New York, New York--(Newsfile Corp. - March 26, 2026) - Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the "Class") who purchas
Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain Officers - NKTR
10:00am, Thursday, 26'th Mar 2026
NEW YORK, March 26, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR) and certain officers
Key Dates and Disclosure Events Shareholders Need to Know NEW YORK, March 26, 2026 /PRNewswire/ -- SueWallSt encourages investors who suffered losses in Nektar Therapeutics (NASDAQ: NKTR) to contact t
NEKTAR THERAPEUTICS (NKTR) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Nektar Therapeutics Investors of Upcoming Deadline
08:26am, Thursday, 26'th Mar 2026
NEW YORK, March 26, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Nektar Therapeutics (“Nektar” or the “Company”) (NASDAQ: NKTR) inv
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit
10:59pm, Wednesday, 25'th Mar 2026
NEW YORK, March 25, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and
NEW YORK, March 25, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 an
Nektar Therapeutics (NKTR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
05:10pm, Wednesday, 25'th Mar 2026
LOS ANGELES, March 25, 2026 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR) have opport
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their Options
Alert: Claims Focus on Alleged Misrepresentations About REZOLVE-AA Patient Enrollment Compliance NEW YORK, March 25, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP reminds purchasers of Nektar Therapeutic
New York, New York--(Newsfile Corp. - March 25, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February
NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky, LLP alerts investors in Nektar Therapeutics (NASDAQ: NKTR) of a pending securities class action. Class Period: February 26, 2025 through December 15, 2025.
Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain Officers – NKTR
03:56pm, Tuesday, 24'th Mar 2026
NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Nektar Therapeutics (“Nektar” or the “Company”) (NASDAQ: NKTR) and certa
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm
01:18pm, Tuesday, 24'th Mar 2026
LOS ANGELES, March 24, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Nektar Therapeutics (“Nektar�
